Introduction
============

Palpable breast mass is a common problem in female patients. The diagnostic delays of breast cancer occur due to the generally low index of suspicion. The traditional diagnosis mode of breast mass is excisional biopsy, which gives a precise diagnosis but may yield a benign pathological result in most cases.

Fine-needle aspiration biopsy (FNAB) of the breast is a minimally invasive diagnostic method, often obviating an open biopsy \[[@B1]\]. It is cheaper to perform and its results can be available within a shorter time. However, the role of FNAB has been challenged of late by better overall results attained by core biopsies. Core biopsy is definitely a robust and reliable diagnostic modality, but carries disadvantages in terms of a longer turn-around due to the tissue processing time, and patient discomfort during the procedure. FNAB has some advantages over core-needle biopsy in that it use a smaller needle and thus has a lower probability of causing hematoma and other rare complications, such as pneumothorax \[[@B2],[@B3]\]

With the introduction of stereotactic and ultrasonographically (US) guided methods for nonpalpable lesions, fine-needle aspiration biopsy (FNAB) have been used more widely in the evaluation of nonpalpable breast lesions \[[@B4]-[@B6]\]. Furthermore, the triple-diagnostic method (consisting of clinical evaluation, mammography and FNAB) gives a precise diagnosis and reduces the risk of missed diagnosis of breast cancer to \< 1% \[[@B7]\].

However, the clinical use of FNAB has been questioned because of the variability in results reported \[[@B8]\] In addition, It is also possible that no cells are harvested making cytological analysis impossible. Many institutes in the United Kingdom, the United States and Canada have now abandoned FNA for diagnosis of breast lesions. Nevertheless, it continues to be used in other institutes in these countries, as well as in Greece, Italy, Australia and Japan, and in developing countries such as India, Pakistan, Nigeria, Mexico and Thailand. Up to now, there was no meta-analysis to establish the overall value of FNAB for the diagnostic breast cancer. The purpose of our study was to establish the overall value of FNAC in the diagnosis of breast lesions.

Materials and methods
=====================

Search strategy and study selection
-----------------------------------

We searched MEDLINE (1966 to 2010), EMBASE (1970 to 2010), the Cochrane Central Register of Controlled Trials (CENTRAL), database of Health Technology Assessments on The Cochrane Library issue 2, 2010 and the China Biological Medicine Database (CBM-disc, 1979 to 2010), VIP Chinese Journals Database (1968 to 2010), China National Knowledge Infrastructure Whole Article Database (CNKI, 1994 to 2010). We also searched the trials registers of Cochrane Breast Cancer Group and the WHO International Clinical Trials Registry at <http://www.who.int/ictrp/en/> for ongoing and recently completed trials. All searches were up to date as of December 2010. The search terms used were \"breast neoplasms\", \"fine-needle aspiration biopsy\", \"Sensitivity and Specificity\" and \"accuracy\". In addition, related keywords and their synonyms were included in our search strategy and reference lists were scanned for additional publications. In order to form a highly sensitive search strategy, there were no restrictions on publication status, or study design. Although no language restrictions were imposed initially, for the full-text review and final analysis, our resources only permitted the review of articles published in the English and Chinese language. Letters, conference abstracts and grey literature to the journal editors were excluded because of the limited data presented.

From the studies obtained in the above search, only those meeting the following criteria were qualified for subsequent analyses: Chinese and English languages, any study designed with at least thirty patients, reporting all-comers populations with suspicious breast lesion after clinic screening. The index biopsy method is fine-needle aspiration biopsy (FNAB) with or without image-guide. Two reviewers (Yinghua Yu, Wei Wei) selected eligible studies independently. Discrepancies were solved by discussion.

Data extraction and quality assessment
--------------------------------------

Data extraction was performed independently by two reviewers (Yinghua Yu, Wei Wei)). The two reviewers were blinded to publication details, and all extracted data had to be agreed upon by them. Data retrieved from the reports including study design, participant characteristics, lesion size, FNAB procedures, outcomes measurement, publication year, and methodological quality. The numbers of true-positive, false-positive, false-negative, and true-negative results are displayed for each study in Table [1](#T1){ref-type="table"}.

###### 

Summary of including studies (Insufficient Samples Excluded in test result)

  study                          year   reference standard   test result   patients (number)   QUADAS score                 
  ------------------------------ ------ -------------------- ------------- ------------------- -------------- ------ ------ ----
  Walker et al.\[[@B33]\]        1998   his                  91            0                   0              19     110    13
  Kanchanabat et al.\[[@B11]\]   2000   his/imag and clin    8             8                   0              26     42     10
  Pisano et al.\[[@B12]\]        2001   his/imag and clin    59            18                  17             183    277    11
  Lumachi et al.\[[@B34]\]       1999   his                  55            0                   2              5      62     10
  Farshid et al.\[[@B35]\]       2008   his/imag and clin    91            120                 2              880    1093   11
  Dennison et al.\[[@B36]\]      2003   his/imag and clin    95            0                   10             38     143    10
  Gent et al.\[[@B37]\]          1986   his                  39            7                   1              109    156    13
  Wanebo et al.\[[@B38]\]        1983   his                  123           8                   1              102    234    13
  Apesteguia et al.\[[@B39]\]    1997   his/imag and clin    2             2                   0              107    111    11
  Manheimer et al.\[[@B40]\]     1977   his                  79            2                   11             35     127    11
  Janet et al.\[[@B41]\]         2010   his/imag and clin    11            0                   4              135    150    9
  Drew et al.\[[@B42]\]          1999   his/imag and clin    102           4                   27             130    263    8
  Masood et al.\[[@B43]\]        1991   his                  17            0                   3              71     91     8
  Ishikawa et al.\[[@B44]\]      2007   his                  138           4                   4              178    324    12
  Harvey et al.\[[@B45]\]        1996   his/imag and clin    14            37                  13             32     96     8
  Leifland et al.\[[@B46]\]      2003   his                  353           11                  52             27     443    11
  Okamoto et al.\[[@B47]\]       1998   his/imag and clin    5             1                   1              125    132    11
  Rubin et al.\[[@B48]\]         1997   his/imag and clin    34            4                   0              27     65     10
  Sauer et al.\[[@B32]\]         2003   his/imag and clin    360           21                  47             321    749    11
  Li et al.\[[@B49]\]            2008   his                  129           1                   22             108    260    9
  Wang et al.\[[@B50]\]          2010   his                  110           2                   7              55     174    13
  Yang et al.\[[@B51]\]          2010   his                  79            0                   4              259    342    11
  Liu et al.\[[@B52]\]           2000   his                  205           1                   12             194    412    10
  Zhao et al.\[[@B53]\]          2009   his                  218           10                  6              241    475    11
  Zhan et al.\[[@B54]\]          2007   his                  32            2                   0              44     78     9
  Gao et al.\[[@B55]\]           2005   his                  169           0                   27             85     281    11
  Lu et al.\[[@B56]\]            2010   his                  102           0                   33             48     183    10
  Liu et al.\[[@B57]\]           2010   his                  5             1                   1              125    132    11
  Zhang et al.\[[@B58]\]         2008   his                  39            6                   4              53     102    11
  Zhang et al.\[[@B59]\]         2006   his                  21            2                   3              31     57     9
  Tang et al.\[[@B60]\]          1987   his                  144           2                   13             144    303    11
  Wang et al.\[[@B61]\]          1995   his                  25            0                   2              22     49     10
  Ma et al.\[[@B62]\]            2010   his                  56            0                   2              99     157    8
  Wang et al.\[[@B63]\]          2010   his                  96            12                  4              498    610    8
  Wang et al.\[[@B64]\]          1981   his                  442           43                  60             479    1024   10
  Wei et al.\[[@B65]\]           2007   his                  91            4                   2              78     175    12
  Tao et al.\[[@B66]\]           2004   his                  655           5                   14             2027   2701   12
  Wang et al.\[[@B67]\]          2005   his                  99            5                   0              207    311    11
  Chen et al.\[[@B68]\]          2010   his                  66            1                   9              176    252    8
  Zeng et al.\[[@B69]\]          1999   his                  94            1                   2              66     163    11
  Jia et al.\[[@B70]\]           1986   his                  49            0                   1              50     100    9
  Ma et al.\[[@B71]\]            2010   his                  68            0                   4              291    363    10
  Huang et al.\[[@B72]\]         2003   his                  305           31                  54             436    826    11
  Zhang et al.\[[@B73]\]         1996   his                  21            1                   2              40     64     9
  Yu et al.\[[@B74]\]            2006   his                  1620          116                 33             359    2128   11
  Jiang et al.\[[@B75]\]         2008   his                  66            1                   9              176    252    11

His: histopathology; imag and clin:imaging and clinical follow-up; TP:true positive; FP: false positive; FN:false negative; TN: true negative.

We assessed the methodological quality of the studies using guidelines published by the quality assessment for studies of diagnostic accuracy (QUADAS) tool \[[@B9]\] \[i.e. appraisal by use of empirical evidence, expert opinion, and formal consensus to assess the quality of primary studies of diagnostic accuracy\]. In addition, for each study the following characteristics of study design were also retrieved: (1) needle gauge (21 gauge vs other size gauge); (2) guidance systems (with ultrasound or stereotactic guidance vs without image guidance); (3) prospective data collection, and (4) geographic location; (5) reference standard (histopathology only or not). If no data on the above criteria were reported in the primary studies, we requested the information from the authors. If the authors did not respond to our letters, the \"unknown\" items were treated as \"no.\"

Statistical analysis
--------------------

We used standard methods recommended for meta-analyses of diagnostic test evaluations \[[@B10]\]. Analyses were performed using RevMan5 software (the Cochrane Information Management System (IMS)), STATA version 10.0 (STATA Corporation, TX, USA) and Meta-DiSc (for Windows; XI Cochrane Colloquium; Barcelona, Spain).

We categorized the cytological results according to The National Cancer Institute recommendation for the diagnosis of breast aspiration cytology:

• Cl = unsatisfactory.

• C2 = cells present all benign; no suspicious features.

• C3 = cells suspicious but probably benign.

• C4 = cells suspicious but probably malignant.

• C5 = Definitely malignant.

This category\' is used when the degree of diagnostic certainty is such that the pathologist would be happy for the patient to undergo major breast surgery on the basis of the cytology sample alone.

We classified the results of FNAB as positive (including class C3, C4, C5) and negative (C2) adapted from Burapa Kanchanabat \[[@B11]\] and Etta D. Pisano \[[@B12]\]. C1 was temporarily exluded from this classification. Our reason for this classification is that solid masses with a FNAB result of intermediate classification (C3, C4,) require other diagnostic procedures to minimized the underestimation. The following measures of test accuracy were computed for each study: sensitivity; specificity; diagnostic odds ratio (DOR); positive likelihood ratio (PLR) and negative likelihood ratio (NLR). As for unsatisfactory samples (C1), it includes disfigured cellular morphology that cannot be interpreted and fewer than five epithelial cell groups. Disputes about unsatisfactory samples were among these studies on account of following therapeutic decisions. In most of the studies, unsatisfactory samples were excluded from analysis while considered to be positive in a study \[[@B12]\]. Since unsatisfactory samples played important roles on therapeutic decisions, we also assessed the sensitivity and specificity for the studies which reported unsatisfactory samples (unsatisfactory samples considered to be positive in our classification) and underestimation rate of unsatisfactory samples.

The analysis was based on a summary receiver operating characteristic (SROC) curve \[[@B13],[@B14]\]. Sensitivity and specificity for the single test threshold identified for each study were used to plot an SROC curve. Random-effects model was used to calculate the average sensitivity, specificity, and the other measures across studies \[[@B15]\].

The term heterogeneity when used in relation to meta-analyses refers to the degree of variability in results across studies. We used the X2 and Fisher exact tests to detect statistically significant heterogeneity. To assess the effects of QUADAS scores on the diagnostic ability of FNAB, we included it as covariates in univariate meta-regression analysis (inverse variance weighted). We also analyzed the effects of other covariates on DOR (ie, publication year, guidance systems, 21 or other size needle gauge, different reference standard, prospective data collection, and different geographic location). The relative DOR (RDOR) was calculated according to standard methods to analyze the change in diagnostic precision in the study per unit increase in the covariate \[[@B16],[@B17]\]. Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the potential presence of this bias using funnel plots \[[@B18]\].

Results
=======

After independent review, 59 publications dealing FNAB for the diagnosis of breast cancer were considered to be eligible for inclusion in the analysis. Of these publications, eight studies \[[@B19]-[@B26]\] were excluded because FNAB was performed only in breast cancer patients, two studies \[[@B27],[@B28]\] were excluded because they evaluated the role of FNAB in diagnosis of axillary lymph nodes, two studies \[[@B29],[@B30]\] were excluded because they did not allow the calculation of sensitivity or specificity or underestimate rate, one studies \[[@B31]\] were excluded because its data had been included as a part of the latest study \[[@B32]\]. Subsequently, 46 studies \[[@B11],[@B12],[@B32]-[@B75]\] including 7207 patients with breast cancer or suspicious features and 9435 patients with benign mass were available for analysis, and the clinical characteristics of these studies, along with QUADAS scores, are outlined in Table [1](#T1){ref-type="table"}. In addition, we derived relative data about unsatisfactory samples from 11 \[[@B11],[@B12],[@B32],[@B33],[@B35],[@B37]-[@B39],[@B44],[@B46],[@B50]\] studies in table [2](#T2){ref-type="table"}.

###### 

Test result of studies (Insufficient Samples Classified as Positive)

  study                          test result   Patients number              
  ------------------------------ ------------- ----------------- ---- ----- ------
  Walker et al.\[[@B33]\]        95            11                0    19    125
  Kanchanabat et al.\[[@B11]\]   8             13                0    26    47
  Pisano et al.\[[@B12]\]        80            149               17   183   429
  Farshid et al.\[[@B35]\]       92            173               2    880   1147
  Gent et al.\[[@B37]\]          39            38                1    109   187
  Wanebo et al.\[[@B38]\]        135           18                1    102   256
  Apesteguia et al.\[[@B39]\]    2             36                0    107   145
  Ishikawa et al.\[[@B44]\]      156           44                4    178   382
  Leifland et al.\[[@B46]\]      406           37                52   27    522
  Sauer et al.\[[@B32]\]         382           82                47   321   832
  Wang et al.\[[@B50]\]          119           5                 7    55    186

TP:true positive; FP: false positive; FN:false negative; TN: true negative.

Study characteristics and quality of studies
--------------------------------------------

As shown in Table [1](#T1){ref-type="table"} and Table [3](#T3){ref-type="table"} the average sample size of the included studies was 362 patients (range, 42 to 2128). Twenty-night studies were performed in Asia; Seventeen studies were conducted in NA (Canada and USA) and Europe. With the exception of one study which was multicenter \[[@B12]\], the others were single center. Most studies were case series (41 retrospective, 5 prospective).

###### 

characteristics of studies

  study                          study design prospective   geographic location Asia   21 needle gauge   Apply imaging guidance systems   histopathology standard only
  ------------------------------ -------------------------- -------------------------- ----------------- -------------------------------- ------------------------------
  Walker et al.\[[@B33]\]        yes                        no                         yes               no                               Yes
  Kanchanabat et al.\[[@B11]\]   yes                        yes                        no                no                               no
  Pisano et al.\[[@B12]\]        yes                        no                         no                yes                              no
  Lumachi et al.\[[@B34]\]       no                         no                         not mention       yes                              yes
  Farshid et al.\[[@B35]\]       yes                        no                         not mention       no                               no
  Dennison et al.\[[@B36]\]      yes                        no                         yes               no                               no
  Gent et al.\[[@B37]\]          no                         no                         no                yes                              yes
  Wanebo et al.\[[@B38]\]        no                         no                         no                yes                              yes
  Apesteguia et al.\[[@B39]\]    no                         no                         no                yes                              no
  Manheimer et al.\[[@B40]\]     no                         no                         no                no                               yes
  Janet et al.\[[@B41]\]         no                         yes                        no                no                               no
  Drew et al.\[[@B42]\]          no                         no                         not mention       no                               no
  Masood et al.\[[@B43]\]        no                         no                         not mention       no                               yes
  Ishikawa et al.\[[@B44]\]      no                         yes                        no                no                               yes
  Harvey et al.\[[@B45]\]        no                         no                         not mention       yes                              no
  Leifland et al.\[[@B46]\]      no                         no                         yes               yes                              yes
  Okamoto et al.\[[@B47]\]       no                         yes                        yes               yes                              no
  Rubin et al.\[[@B48]\]         no                         no                         not mention       no                               no
  Sauer et al.\[[@B32]\]         no                         no                         not mention       yes                              no
  Li et al.\[[@B49]\]            no                         yes                        not mention       no                               yes
  Wang et al.\[[@B50]\]          no                         yes                        not mention       no                               yes
  Yang et al.\[[@B51]\]          no                         yes                        not mention       no                               yes
  Liu et al.\[[@B52]\]           no                         yes                        not mention       no                               yes
  Zhao et al.\[[@B53]\]          no                         yes                        yes               no                               yes
  Zhan et al.\[[@B54]\]          no                         yes                        yes               no                               yes
  Gao et al.\[[@B55]\]           no                         yes                        yes               no                               yes
  Lu et al.\[[@B56]\]            no                         yes                        no                yes                              yes
  Liu et al.\[[@B57]\]           no                         yes                        yes               yes                              yes
  Zhang et al.\[[@B58]\]         no                         yes                        no                no                               yes
  Zhang et al.\[[@B59]\]         no                         yes                        yes               yes                              yes
  Tang et al.\[[@B60]\]          no                         yes                        yes               no                               yes
  Wang et al.\[[@B61]\]          no                         yes                        no                yes                              yes
  Ma et al.\[[@B62]\]            no                         yes                        no                no                               yes
  Wang et al.\[[@B63]\]          no                         yes                        no                no                               yes
  Wang et al.\[[@B64]\]          no                         yes                        yes               no                               yes
  Wei et al.\[[@B65]\]           no                         yes                        yes               no                               yes
  Tao et al.\[[@B66]\]           no                         yes                        no                no                               yes
  Wang et al.\[[@B67]\]          no                         yes                        yes               no                               yes
  Chen et al.\[[@B68]\]          no                         yes                        yes               no                               yes
  Zeng et al.\[[@B69]\]          no                         yes                        no                no                               yes
  Jia et al.\[[@B70]\]           no                         yes                        yes               no                               yes
  Ma et al.\[[@B71]\]            no                         yes                        no                no                               yes
  Huang et al.\[[@B72]\]         no                         yes                        yes               no                               yes
  Zhang et al.\[[@B73]\]         no                         yes                        yes               no                               yes
  Yu et al.\[[@B74]\]            no                         yes                        yes               no                               yes
  Jiang et al.\[[@B75]\]         no                         yes                        yes               no                               yes

The age of patients ranged from 26 to 87 years. Risk factors for cancer in the selected population, i.e., family history, genetic predisposition, menopausal status, and/or prior high risk lesions, were rarely reported. Needle size has varied from 20 to 25 gauge in these studies, 15 studies used 21-gauge size while the others used 20, 22, 23, 25 size or didn\'t mentioned it. Four studies used stereotactic guidance systems; five studies used ultrasound systems; four studies used stereotactic or ultrasound guidance systems according to the breast mass; the rest studies performed FNAB without any kind of imaged guidance systems. Two outcome measurements were adopted by these studies. As histopathologic results from surgical biopsy was regarded as gold standard in this field, patients with malignant lesions, cells suspicious, or when requested, subsequently underwent open surgery in all these studies. In case of benign lesions (breast cysts and a benign cytological result from low-risk patients), clinical and imaged follow-up at least 6 months was adopted by some studies while most of the studies still have involved comparison of FNAB benign findings with histopathologic results from core-needle biopsy or open surgical biopsy.

We assessed the quality of the studies using QUADAS. Out of 14 QUADAS items, item 1 (spectrum composition) and item 2 (selection criteria) are about the variability of studies, item 8 (index test execution), 9 (reference standard execution) and 13 (uninterpretable test results) are about the quality of reporting, the rest of the items are about the bias of studies. If criterion was fulfilled, the item was signed \"yes\"; if not, the item was signed \"no\"; if study did not report clearly and we could not request the information from the authors, the item was signed \"unknown\". As shown in Table [4](#T4){ref-type="table"}, item 1 and 2 were 91% and 100% fulfilled by studies respectively; item 8, 9, 13 were 80%, 100%, 24%; in the rest of the items assessed bias reached a high level, except item 11 (reference standard review bias) and 14 (withdrawals).

###### 

methodological quality of 46 studies

               QUADAS item                                                                     
  ------------ ------------- ----- ----- ---- ----- ---- ----- ---- ----- ----- ---- ---- ---- ----
  Yes(n)       42            46    46    40   46    35   46    37   46    46    7    39   11   13
  No(n)        4             0     0     0    0     11   0     5    0     0     0    0    0    3
  Unknown(n)   0             0     0     6    0     0    0     4    0     0     39   7    35   30
  Yes(%)       91            100   100   87   100   76   100   80   100   100   15   85   24   28

n: number of studies

Diagnostic accuracy
-------------------

Figure [1](#F1){ref-type="fig"} shows the forest plot of sensitivity and specificity for FNAB in the diagnosis of breast cancer (C1 was temporarily exluded). The sensitivity ranged from 0.52 to 1.00 (mean, 0.927; 95% confidence interval \[CI\], 0.921 to 0.933), and specificity ranged from 0.46 to 1.00 (mean, 0.948; 95% CI, 0.943 to 0.952). We also noted that PLR was 25.72 (95% CI, 17.35 to 28.13), NLR was 0.08 (95% CI, 0.06 to 0.11), and DOR was 429.73 (95% CI, 241.75 to 763.87). X2 values of sensitivity, specificity, PLR, NLR, and DOR were 437.15 (p \< 0.001), 840.00 (p \< 0.001), 653.52 (p \< 0.001), 464.80 (p \< 0.001), and 396.91 (p \< 0.001), respectively, with all indicating a significant heterogeneity between studies.

![**Forest plot of estimates of sensitivity and specificity for FNAB (C1 was temporarily exluded) in the diagnosis of breast cancer**. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. The authors\' names indicate the studies.](1471-2407-12-41-1){#F1}

The SROC curve presents a global summary of test performance, and shows the tradeoff between sensitivity and specificity. A graph of the SROC curve for the biopsy results of FNAB (C1 was temporarily exluded) showing true-positive rates vs false-positive rates from individual studies is shown in Figure [2](#F2){ref-type="fig"}. Our data showed that the SROC curve is positioned near the desirable upper left corner of the SROC curve, and that the maximum joint sensitivity and specificity (ie, the Q-value) was 0.948; while the area under the curve (AUC) was 0.986, indicating a high level of overall accuracy.

![**SROC curves for FANB (C1 was temporarily exluded)**. Each study is represented by each solid circle in the meta-analysis. The size of the solid circle indicates the size of each study. SROC curves summarize the overall diagnostic accuracy.](1471-2407-12-41-2){#F2}

Since unsatisfactory samples played important roles on therapeutic decisions, we assessed the pooled sensitivity and specificity for FNAB in the diagnosis of breast cancer in these 11 studies \[[@B11],[@B12],[@B32],[@B33],[@B35],[@B37]-[@B39],[@B44],[@B46],[@B50]\], which reported unsatisfactory samples (C1 was considered to be positive in this classification). As Figure [3](#F3){ref-type="fig"} shows, the pooled sensitivity and specificity for this group were 0.920 (95% CI, 0.906 to 0.933; X2 = 71.53, p \< 0.001) and 0.768 (95% CI, 0.751 to 0.784; X2 = 163.02, p \< 0.001) respectively. This graph of the SROC curve is shown in Figure [4](#F4){ref-type="fig"}. The maximum joint sensitivity and specificity was 0.815; while the area under the curve (AUC) was 0.884. In addition, we calculated and displayed the underestimation rates of unsatisfactory samples between FNAB and histopathologic standard in table [5](#T5){ref-type="table"}. The pooled proportion of these unsatisfactory samples that were subsequently upgraded to various grade cancers was 27.5% (95% CI, 0.221 to 0.296), X2 values was 159.85 (p \< 0.001). This p-values also indicated significant heterogeneity between studies.

![**Forest plot of estimates of sensitivity and specificity for FNAB in 11 studies which reported insufficient samples**. Insufficient samples considered to be positive.](1471-2407-12-41-3){#F3}

![**SROC curves for FANB of 11 studies which reported insufficient samples (insufficient samples was considered to be positive)**. Each study is represented by each solid circle in the meta-analysis. The size of the solid circle indicates the size of each study. SROC curves summarize the overall diagnostic accuracy.](1471-2407-12-41-4){#F4}

###### 

Summary underestimation rate of unsatisfactory samples using meta-analysis

                           n    a     b     pooled under-estimation rate   95%CI         X^2^     P-value
  ------------------------ ---- ----- ----- ------------------------------ ------------- -------- ------------
  unsatisfactory Samples   11   140   545   25.7%                          0.221-0.296   159.85   p \< 0.001

n = number of studies; a = number of breast cancer or Low grade cancers; b = total number of unsatisfactory Samples;

Multiple regression analysis and publication bias
-------------------------------------------------

We used meta-regression to assess the different aspects among 46 studies: with or without 21-gauge, with or without imaging guidance systems, standard reference adopted histopathology only, located in Asia, prospective designs and QUADAS scores. Quality scoring was done by the use of QUADAS \[[@B76]\], in which a score of 1 was given when a criterion was fulfilled, 0 if a criterion was unclear, and -1 if the criterion was not achieved. As was shown in table [1](#T1){ref-type="table"}, the studies were with relative high quality if its score was more than ten. These scores were used in the meta-regression analysis to assess the effect of study quality on the RDOR of FNAB in the diagnosis of breast mass. The table [6](#T6){ref-type="table"} showed that excepted two aspects (with or without imaging guidance systems, standard reference adopted histopathology only), the rest aspects mentioned above did not substantially affect the diagnostic accuracy as their differences did not reach statistical significance (p \> 0.05).

###### 

meta-regression of the effects of six different studies\' aspects on diagnosis value of FNAB

  Covariates                 Number of studies   Coefficient   RDOR   95%CI        P-value
  -------------------------- ------------------- ------------- ------ ------------ ---------
  QUADAS ≥ 10                34                  0.747         2.11   0.60-7.47    0.2389
  21-gauge                   19                  -0.705        0.49   0.16-1.53    0.2149
  imaging guidance systems   13                  -1.383        0.25   0.07-0.95    0.0417
  histopathology only        35                  1.705         5.5    1.04-29.08   0.0451
  prospective                5                   0.74          2.1    0.25-17.36   0.4829
  Asia                       31                  0.433         1.56   0.33-7.43    0.5696

The funnel plots for publication bias (Figure [5](#F5){ref-type="fig"}) showed large asymmetry. These results indicated a potential for publication bias.

![**Funnel graph for the assessment of potential publication bias in FNAB**. The funnel graph plots the log of the DOR against the SE of the log of the DOR (an indicator of sample size). Forty-six circle represents forty-six studies in the meta-analysis. The line in the centre indicates the summary diagnostic odds ratio.](1471-2407-12-41-5){#F5}

Discussion
==========

Our current meta-analysis presented the high level diagnostic accuracy of Fine-needle aspiration biopsy (FNAB). In our first classification (C1 was temporarily exluded as most studies did.), the sensitivity rate was 92.7% and the specified rate was nearly 94.8%. The SROC curve showed the maximum joint sensitivity and specificity (i.e. the Q-value) was 0.948; while the area under the curve (AUC) was 0.986, presenting excellent level of overall accuracy.

The DOR is a single indicator of test accuracy \[[@B77]\] that combines the data from sensitivity and specificity into a single number. The DOR of a test is the ratio of the odds of positive test results in the patient with disease relative to the odds of positive test results in the patient without disease. The value of a DOR ranges from 0 to infinity, with higher values indicating better discriminatory test performance (i.e. higher accuracy). A DOR of 1.0 indicates that a test does not discriminate between patients with the disorder and those without it. In the present meta-analysis, we have found that the mean DOR was 429.73, also indicating a high level of overall accuracy.

Since the SROC curve and the DOR are not easy to interpret and use in clinical practice, and since likelihood ratios are considered to be more clinically meaningful \[[@B78],[@B79]\], we also presented both PLR and NLR as our measures of diagnostic accuracy. Likelihood ratios of \> 10 or \< 0.1 generate large and often conclusive shifts from pre-test to post-test probability (indicating high accuracy) \[[@B79]\]. In our first classification, PLR value of 25.72 suggests that patients with various grade cancers have an approximately 26-fold higher chance of being FNAB result-positive compared with patients with benign breast lesion. This high probability would be considered high enough to begin surgical treatment or other therapy. On the other hand, NLR was found to be 0.08 in our current meta-analysis. If the FNAB result was negative, the probability that this patient has breast carcinoma is approximately 8%.

It should be emphasized that we used the approach of Burapa Kanchanabat \[[@B11]\] and Etta D. Pisano \[[@B12]\] for evaluating the diagnostic performance of FNAB (1. unsatisfactory samples was temporarily excluded; 2. unsatisfactory samples was classified as positive). In our first classification, unsatisfactory samples (C1) was exluded as most studies did. In our second classification, Inadequate cytological material have to be interpreted as \"positive\". Because treating the unsatisfactory result as a negative outcome is a poor policy that has the potential to cause harm to patients and delay the diagnosis of breast cancer. On the purpose of minimizing the chance of a missed diagnosis of breast cancer, certain discrepancies between FNAB and open biopsy (e.g. cytological results including C3, C4, C5 on FNAB and atypical hyperplasia or various grades cancer on open biopsy) were considered as agreements and needed further management. The reclassified agreement rate is therefore a clinically relevant and pragmatic estimate for the accordance between FNAB and actual disease status.

Breast cancer was present in certain proportion of the inadequate FNAB specimens. Since unsatisfactory samples (C1) played important roles in influencing diagnostic accuracy of FNAB, we also assessed the pooled sensitivity and specificity for FNAB in the other classification (unsatisfactory samples were regarded as positive) and the underestimation rate of unsatisfactory samples. This pooled sensitivity (92.7%) was similar with the sensitivity (92.0%) that mentioned above in our first classification (unsatisfactory samples was exluded) while the pooled specificity (76.8%) was lower than the specificity (94.8%) above. This change may be due to the underestimation rate of inadequate samples which was currently assessed in our study. This pooled unsatisfactory samples\' underestimate rate was 27.5% which was higher than the value (8.5%) reported by H.C.Lee \[[@B80]\]. However, we included more recent related studies and more patients than H.C.Lee did. Our underestimate rate indicated that 27.5% of the patients with a diagnosis of inadequate samples for cytological analysis will prove to have various grades breast cancer. This rate was not low enough to rule out breast cancer. So, in most of these cases, an additional managemant such as core biopsies or surgical procedure will then be necessary.

On the whole, the quality of the included studies is higher than median level according to QUADAS. Many studies did not reach item 11 (reference standard review bias), 13 (uninterpretable test results) or 14 (withdrawals). According to QUADAS items and studies\' detail analysis, most studies did not mention blinding results interpreted, uninterpretable test results or explained withdrawals which did not match item 11, 13 and 14. These bias would affect the analysis of accuracy of FNAB.

An exploration of the reasons for heterogeneity rather than the computation of a single summary measure was an important goal of meta-analysis \[[@B81]\]. In our meta-analysis, QUADAS scores were used in the meta-regression analysis to assess the effect of study quality on RDOR. We did not observe that the studies with relatively higher quality (QUADAS score of ≥10) had better test performances than those with lower quality.

Although we found a significant heterogeneity for sensitivity, specificity, PLR, NLR and DOR among the studies analyzed, meta-regression results showed that 3 different aspects among 46 studies (such as needle size, study locations and prospective/retrospective designs) didn\'t reach statistical significance, indicating that these aspects did not substantially affect diagnostic accuracy. On the other hand, 2 different aspects such as guidance systems (with ultrasound or stereotactic guidance vs without imaging guidance) and reference standard (histopathology only or not) affect the diagnostic accuracy in great part. These may be due to the following reasons. First, fine-needle aspiration biopsy without imaging guidance is not suitable for patients with ill-defined masses because the aspiration cannot be done at the exact position and the cytological result may not represent the true nature of the mass. In other words, breast lesions could be definitely localized by imaging guidance then FNAB could be done. FNAB with imaging guidance system can make a favorite diagnosic accuracy. Second, there were the combined two standard methods adopted by some included studies, surgery biopsy for suspicious lesion and imaging or clinic follow-up for benign cytological result from low-risk patients. Moreover, the time of follow-up is different from each other (range from 6-24 months). As a result, misclassification may occur easier in this two different reference standard situation than in that histopathologic is the only reference standard.

Apart for having a comprehensive search strategy, our study assessed the FNAB diagnosis accuracy in all directions, such as sensitivity, specificity, PLR, NLR, DOR, SROC curve and AUC. In addition, we assessed the influence of unsatisfactory samples on FNAB diagnosis accuracy. Heterogeneity and potential publication bias were also explored in accordance with published guidelines. However, our systematic review had some limitations. Only including English and Chinese language studies and the lack of conference abstracts, letters to editors might have led to publication bias.

Conclusion
==========

On the whole, our current evidence shows that fine-needle aspiration biopsy (FNAB) is an accurate biopsy for evaluating breast malignancy if rigorous criteria are used. With high sensitivity and specificity, most benign and malignant breast lesions can be reliably diagnosed by FNAB. FNAB may provide a favorable screening method and permit an improvement of treatment planning. With the introduction of imaging guided methods for percutaneous sampling of nonpalpable lesions, FNAB can be used more widely in the evaluation of breast lesions

However, as unsatisfactory samples\' underestimate rate (27.5%) is not low enough to rule out malignant, the result of C1 for cytological analysis in FNAB warrants futher invasive procedures including core biopsies or open surgical biopsy in order to minimize the chance of missed diagnosis of breast cancer. Fine needle aspiration continues to be an acceptable and reliable procedure for the preoperative diagnosis of breast lesions, particularly in developing countries
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